Designing enzymes with protective shells that are cleaved once they arrive at inflammatory sites can be used to enhance immune therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Adams, G., Vessillier, S., Dreja, H. & Chernajovsky, Y. Nat. Biotechnol. 21, 1314–1320 (2003).
Jacobs, L. et al. Arch. Neurol. 44, 589–595 (1987).
van Meurs, J. et al. Arth. Rheum. 42, 2074–2084 (1999).
Gijbels, K., Galardy, R. & Steinman, L. J. Clin. Invest. 94, 2177–2182 (1994).
Croxford, J.L. et al. J. Immunol. 160, 5181–5187 (1998).
Garren, H. et al. Immunity 15, 15–22 (2001).
Lode, H.N., Xiang, R., Becker, J.C., Gillies, S.D. & Risfeld, R.A. Pharmacol. Ther. 80, 277–292 (1998).
Karpuj, M.V. et al. Nat. Med. 8, 143–149 (2002).
von Adrian, U. & Engelhart, B. N. Engl. J. Med. 348, 68–73 (2003).
Feldmann, M. & Maini, R.N. Nat. Med. 9, 1245–1250 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steinman, L. Engineering better cytokines. Nat Biotechnol 21, 1293–1294 (2003). https://doi.org/10.1038/nbt1103-1293
Issue Date:
DOI: https://doi.org/10.1038/nbt1103-1293
This article is cited by
-
Design of effective immunotherapy for human autoimmunity
Nature (2005)